These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27748523)

  • 41. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
    Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
    J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
    Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
    Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
    Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
    J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
    Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
    Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The serine/threonine kinase Pim-1.
    Bachmann M; Möröy T
    Int J Biochem Cell Biol; 2005 Apr; 37(4):726-30. PubMed ID: 15694833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro.
    Ming LG; Lv X; Ma XN; Ge BF; Zhen P; Song P; Zhou J; Ma HP; Xian CJ; Chen KM
    Endocrinology; 2013 Mar; 154(3):1202-14. PubMed ID: 23389955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts.
    Kalbasi Anaraki P; Patecki M; Tkachuk S; Kiyan Y; Haller H; Dumler I
    J Bone Miner Res; 2015 Feb; 30(2):379-88. PubMed ID: 25196912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
    Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
    Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors.
    Ohyama Y; Ito J; Kitano VJ; Shimada J; Hakeda Y
    PLoS One; 2018; 13(1):e0191192. PubMed ID: 29342179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
    Jöhrer K; Obkircher M; Neureiter D; Parteli J; Zelle-Rieser C; Maizner E; Kern J; Hermann M; Hamacher F; Merkel O; Wacht N; Zidorn C; Scheideler M; Greil R
    J Mol Med (Berl); 2012 Jun; 90(6):681-93. PubMed ID: 22205266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation.
    Ang ES; Yang X; Chen H; Liu Q; Zheng MH; Xu J
    FEBS Lett; 2011 Sep; 585(17):2755-62. PubMed ID: 21835177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
    Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
    Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
    Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
    PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis.
    Lombardi MS; Gilliéron C; Berkelaar M; Gabay C
    PLoS One; 2017; 12(10):e0185426. PubMed ID: 28973003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The multiple myeloma bone eco-system and its relation to oncogenesis.
    Bataille R
    Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity.
    Yao J; Li J; Zhou L; Cheng J; Chim SM; Zhang G; Quinn JM; Tickner J; Zhao J; Xu J
    J Cell Physiol; 2015 Jun; 230(6):1235-42. PubMed ID: 25363829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge.
    Kim HH; Kim JH; Kwak HB; Huang H; Han SH; Ha H; Lee SW; Woo ER; Lee ZH
    Biochem Pharmacol; 2004 May; 67(9):1647-56. PubMed ID: 15081864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
    Nair JR; Caserta J; Belko K; Howell T; Fetterly G; Baldino C; Lee KP
    Leukemia; 2017 Aug; 31(8):1715-1726. PubMed ID: 28008178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pim2 is important for regulating DNA damage response in multiple myeloma cells.
    Ramachandran J; Santo L; Siu KT; Panaroni C; Raje N
    Blood Cancer J; 2016 Aug; 6(8):e462. PubMed ID: 27564460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.